MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
Status:
Recruiting
Trial end date:
2026-08-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit
of elranatamab in combination with other anti-cancer therapies in participants with multiple
myeloma.